Targeting miR‐126 disrupts maintenance of myelodysplastic syndrome stem and progenitor cells
Clinical and Translational Medicine2021Vol. 11(10), pp. e610–e610
Citations Over Time
Huafeng Wang, Jie Sun, Bin Zhang, Dandan Zhao, Hongyan Tong, Herman Wu, Xia Li, Yingwan Luo, Dan Dong, Yiyi Yao, Tinisha McDonald, Anthony S. Stein, Monzr M. Al Malki, Flavia Pichiorri, Nadia Carlesso, Ya‐Huei Kuo, Guido Marcucci, Ling Li, Jie Jin
Abstract
MiR-126 plays crucial roles in MDS HSPC maintenance. Therapeutic targeting of miR-126 is a potentially novel approach in MDS.
Related Papers
- Determination of the effects of biomaterials on human peripheral blood mononuclear cells (PBMC)(2002)
- → Comparative in vitro bioactivity of cyclosporine on the proliferation of cultured peripheral blood mononuclear cells (PBMC) in sarcoidosis patients (SP) and healthy controls (HC)(2004)
- → Cytoplasmatic Expression of CD34 in Acute Leukemia(1998)
- → Myelodysplastic Syndromes (MDS)(2018)
- → Progenitor cells and circulating endothelial cells are associated with disease activity and damage in systemic lupus erythematosus patients(2023)